← Issue №10/ week of Sep 6, 2026/Hepatology

Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology review · Sep 2, 2026 · J Hepatology · IF 40.1

Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.

New evidencehepatocellular carcinomabiomarkercost-effectivenesshealth services
Clinical takeawayConsider NC-aMRI as an alternative to ultrasound for HCC surveillance in patients with cirrhosis or high-risk chronic HBV (e.g., active hepatitis, family history of HCC), particularly where adherence or ultrasound sensitivity is a concern. Note: NC-aMRI avoids contrast but requires further validation for broader adoption. No clinical action yet for blood-based biomarkers: pending validation in prospective studies.
What it foundNon-contrast abbreviated MRI (NC-aMRI) showed superior sensitivity and specificity compared to ultrasound for HCC surveillance in recent trials.
ContextChallenges current guideline-recommended ultrasound + AFP surveillance, which has suboptimal sensitivity and lacks RCT evidence for mortality benefit. Proposes benefit stratification over risk stratification alone.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)

Decision at stakewhether to adopt abbreviated MRI or biomarker panels for HCC surveillance

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. … Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.

AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834) · reviewed 2026-10-25 ↗
Ioannou GN … Rowe IA · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues